Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Effects of LY2605541 on Respiratory Quotient During Sleep and Response to Hyperinsulinemia Compared With That of Insulin Glargine in Patients With Type 1 Diabetes Mellitus (BIDO)

Next Previous
Search
Trial Profile

Evaluation of the Effects of LY2605541 on Respiratory Quotient During Sleep and Response to Hyperinsulinemia Compared With That of Insulin Glargine in Patients With Type 1 Diabetes Mellitus (BIDO)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Mar 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin peglispro (Primary) ; Insulin glargine
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms BIDO

    • Most Recent Events

    • 24 Mar 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 27 Oct 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 14 Aug 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top